Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This clinical study evaluates the 12-week efficacy and safety of Epinephrine HFA Inhalation
Aerosol HFA the proposed HFA formulation of metered dose inhaler (MDI) of Epinephrine, in
comparison to a Placebo-HFA control MDI and the currently marketed Primatene® Mist
(epinephrine CFC inhaler), in adolescent and adult subjects with asthma.